(redirected from Dyslipidaemia)
Also found in: Medical.


An abnormal concentration of lipids or lipoproteins in the blood.

dys·lip′i·de′mic (-mĭk) adj.


n dislipidemia
Mentioned in ?
References in periodicals archive ?
Berberis aristata DC (commonly known as Tree turmeric or Indian Barberry) has previously demonstrated beneficial effects in dyslipidaemia with significant reductions in total cholesterol (TC) and low-density lipoprotein (LDL) cholesterol attributed to up-regulation of LDL-receptor expression.
Dyslipidaemia is an independent risk factor for cardiovascular disease and progression of CKD.
Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated to reduce elevated total cholesterol, LDL-C, Apo B, and triglyceride, and increase HDL-C in adults with primary hypercholesterolaemia and mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e.
Likewise, around half of overweight subjects, and 15-45% of obese subjects, appear to have a favourable metabolic profile (that is, no metabolic complications, inflammation, dyslipidaemia, or hypertension).
The diagnoses of cardiovascular events, T2DM, hypertension, dyslipidaemia, peripheral neuropathy, diabetic retinopathy, and nephropathy were based on self-reports, confirmed by hospital medical records and further clinical examinations carried out at the time of the survey.
23) Diabetic dyslipidaemia is characterised by elevated levels of triglyceride rich lipoproteins known as very low density lipoproteins (VLDL) and reduced levels of high density lipoproteins (HDL), with low density lipoproteins dominating.
This approach has also been shown to increase total limb fat by approximately 400-500 g per year, but has the disadvantage of possible increased dyslipidaemia (with all PIs except ATV).
Rl, Director, Carbohydrate and Lipid Metabolism Research Unit at the University of Witwatersand in Johannesburg, said another diabetic symptom, dyslipidaemia, is often neglected although it is prevalent in 366 million people worldwide.
The guidelines recommend an assessment of cardiovascular risk at least once every five years for all adults aged 40 or above who are not assumed to be at high CVD risk based on clinical history, and individuals at any age with a first-degree relative who has premature atherosclerotic CVD or familial dyslipidaemia.
Results indicate that Lingzhi might have mild antidiabetic effects and potentially improve the dyslipidaemia of diabetes, as shown previously in some animal studies.
Screening programmes for modifiable risk factors in shift workers have yielded substantial burdens of treatable risk factors, including dyslipidaemia [ie high cholesterol], smoking, glucose intolerance, and hypertension.
The effective correction by 4HO-Ile of the dyslipidaemia is similar to results of 4HO-Ile treatment of rats or mice with a type 2 diabetes phenotype, in which 4HO-Ile induced improvements in both lipid profile and hyperglycaemia (Haeri et al.